跳至主要内容
临床试验/TCTR20170808001
TCTR20170808001进行中(未招募)4 期

A Retrospective Study of the Efficacy and Safety of Hema-Plus (Recombinant Human Erythropoietin Alfa) in Patients with Chronic Kidney Disease who continuously used Hema-Plus at Siriraj Hospital

Apexcela Co., Ltd.0 个研究点目标入组 200 人开始时间: 2017年8月8日最近更新:
适应症

试验速览

阶段
4 期
状态
进行中(未招募)
发起方
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
0 N/A (No limit) 至 0 N/A (No limit)(—)
性别
All

入选标准

  • Each patient included in the review must meet all of the following criteria to be in this study:
  • 1.Presented with chronic kidney disease
  • 2.History of receiving Hema-Plus for at least 6 months during the study period

排除标准

  • 1.Subjects who met inclusion criteria but their medical records are not available for access.

研究者

发起方
Apexcela Co., Ltd.

相似试验